Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
Identifieur interne : 003F93 ( Main/Exploration ); précédent : 003F92; suivant : 003F94Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
Auteurs : RBID : pubmed:9098191English descriptors
- KwdEn :
- Antibodies, Bispecific (diagnostic use), Carcinoembryonic Antigen (analysis), Carcinoembryonic Antigen (immunology), Carcinoma, Non-Small-Cell Lung (blood), Carcinoma, Non-Small-Cell Lung (pathology), Carcinoma, Non-Small-Cell Lung (radionuclide imaging), Carcinoma, Non-Small-Cell Lung (surgery), Haptens (diagnostic use), Humans, Immunohistochemistry, Indium Radioisotopes (diagnostic use), Lung Neoplasms (immunology), Lung Neoplasms (pathology), Lung Neoplasms (radionuclide imaging), Lung Neoplasms (surgery), Mediastinum (radionuclide imaging), Neoplasm Staging, Pentetic Acid (diagnostic use), Radioimmunodetection (methods), Sensitivity and Specificity.
- MESH :
- chemical , analysis : Carcinoembryonic Antigen.
- chemical , diagnostic use : Antibodies, Bispecific, Haptens, Indium Radioisotopes, Pentetic Acid.
- chemical , immunology : Carcinoembryonic Antigen.
- blood : Carcinoma, Non-Small-Cell Lung.
- immunology : Lung Neoplasms.
- methods : Radioimmunodetection.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- radionuclide imaging : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mediastinum.
- surgery : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- Humans, Immunohistochemistry, Neoplasm Staging, Sensitivity and Specificity.
Abstract
Immunoscintigraphy (IS) using anti-CEA F(ab')2 monoclonal antibody (MAb) is useful for improving mediastinal staging of nonsmall cell lung cancer (NSCLC), but the technique was limited because of an insufficient contrast between tumor and normal tissues. The aim of this study was to determine if the method could be improved by a two-step method which uses a bispecific anti-CEA/anti-di-DTPA antibody (Bs-MAb) and 111In-labeled di-DTPA-tyrosyl-lysine bivalent hapten.
PubMed: 9098191
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.</title><author><name sortKey="Vuillez, J P" uniqKey="Vuillez J">J P Vuillez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, CHU de Grenoble Centre Catherine de Sienne, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, CHU de Grenoble Centre Catherine de Sienne, Nantes</wicri:regionArea><placeName><region type="région">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Moro, D" uniqKey="Moro D">D Moro</name></author><author><name sortKey="Brichon, P Y" uniqKey="Brichon P">P Y Brichon</name></author><author><name sortKey="Rouvier, E" uniqKey="Rouvier E">E Rouvier</name></author><author><name sortKey="Brambilla, E" uniqKey="Brambilla E">E Brambilla</name></author><author><name sortKey="Barbet, J" uniqKey="Barbet J">J Barbet</name></author><author><name sortKey="Peltier, P" uniqKey="Peltier P">P Peltier</name></author><author><name sortKey="Meyer, P" uniqKey="Meyer P">P Meyer</name></author><author><name sortKey="Sarrazin, R" uniqKey="Sarrazin R">R Sarrazin</name></author><author><name sortKey="Brambilla, C" uniqKey="Brambilla C">C Brambilla</name></author></titleStmt><publicationStmt><date when="1997">1997</date><idno type="RBID">pubmed:9098191</idno><idno type="pmid">9098191</idno><idno type="wicri:Area/Main/Corpus">004392</idno><idno type="wicri:Area/Main/Curation">004392</idno><idno type="wicri:Area/Main/Exploration">003F93</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Bispecific (diagnostic use)</term><term>Carcinoembryonic Antigen (analysis)</term><term>Carcinoembryonic Antigen (immunology)</term><term>Carcinoma, Non-Small-Cell Lung (blood)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Carcinoma, Non-Small-Cell Lung (radionuclide imaging)</term><term>Carcinoma, Non-Small-Cell Lung (surgery)</term><term>Haptens (diagnostic use)</term><term>Humans</term><term>Immunohistochemistry</term><term>Indium Radioisotopes (diagnostic use)</term><term>Lung Neoplasms (immunology)</term><term>Lung Neoplasms (pathology)</term><term>Lung Neoplasms (radionuclide imaging)</term><term>Lung Neoplasms (surgery)</term><term>Mediastinum (radionuclide imaging)</term><term>Neoplasm Staging</term><term>Pentetic Acid (diagnostic use)</term><term>Radioimmunodetection (methods)</term><term>Sensitivity and Specificity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Carcinoembryonic Antigen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Antibodies, Bispecific</term><term>Haptens</term><term>Indium Radioisotopes</term><term>Pentetic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Carcinoembryonic Antigen</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radioimmunodetection</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term><term>Mediastinum</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Immunohistochemistry</term><term>Neoplasm Staging</term><term>Sensitivity and Specificity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immunoscintigraphy (IS) using anti-CEA F(ab')2 monoclonal antibody (MAb) is useful for improving mediastinal staging of nonsmall cell lung cancer (NSCLC), but the technique was limited because of an insufficient contrast between tumor and normal tissues. The aim of this study was to determine if the method could be improved by a two-step method which uses a bispecific anti-CEA/anti-di-DTPA antibody (Bs-MAb) and 111In-labeled di-DTPA-tyrosyl-lysine bivalent hapten.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9098191</PMID><DateCreated><Year>1997</Year><Month>05</Month><Day>05</Day></DateCreated><DateCompleted><Year>1997</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0161-5505</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>4</Issue><PubDate><Year>1997</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation></Journal><ArticleTitle>Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.</ArticleTitle><Pagination><MedlinePgn>507-11</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Immunoscintigraphy (IS) using anti-CEA F(ab')2 monoclonal antibody (MAb) is useful for improving mediastinal staging of nonsmall cell lung cancer (NSCLC), but the technique was limited because of an insufficient contrast between tumor and normal tissues. The aim of this study was to determine if the method could be improved by a two-step method which uses a bispecific anti-CEA/anti-di-DTPA antibody (Bs-MAb) and 111In-labeled di-DTPA-tyrosyl-lysine bivalent hapten.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twelve patients were intravenously given a 30 min Bs-MAb infusion (0.1 mg/kg). Four days later, they were injected intravenously with 0.1 microgram/kg hapten labeled with 185 MBq 111In (5 mCi). Images were recorded immediately and 6 and 24 hr after hapten injection. A pharmacokinetic analysis was performed. Surgery was performed 3 days after 111In-hapten injection, and samples of tumor and normal tissues were collected for immunohistochemical and biodistribution studies. IS results were classified as true-positive (TP), false-positive (FP), true-negative (TN) or false-negative (FN) according to the surgical data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Primary tumors were visualized in nine patients. The contrast was excellent, generally higher than that obtained with direct labeling of anti-CEA. In the mediastinum, IS results were (after surgery) five TN, two TP and one FP. One case remains undetermined. The FP result was due to a Bs-MAb uptake in intrapulmonary lymph nodes. IS was in agreement with preoperative staging in six of these nine patients and discordant in three.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study confirmed that the two-step method with a bispecific antibody could greatly improve the performances of IS for lung cancer staging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vuillez</LastName><ForeName>J P</ForeName><Initials>JP</Initials><Affiliation>Department of Nuclear Medicine, CHU de Grenoble Centre Catherine de Sienne, Nantes, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Brichon</LastName><ForeName>P Y</ForeName><Initials>PY</Initials></Author><Author ValidYN="Y"><LastName>Rouvier</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Brambilla</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Peltier</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sarrazin</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Brambilla</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Haptens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName MajorTopicYN="N">analysis</QualifierName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName MajorTopicYN="N">blood</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Haptens</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mediastinum</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunodetection</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9098191</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9098191
|texte= Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9098191" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |